Stocks

FDA order may sink Themis Medicare

| Updated on July 13, 2018 Published on July 12, 2018

Themis Medicare, maker of diclofenac 1 ml injection, has been directed by the Food and Drug Administration authorities to stop manufacturing a key product. The company has been given an opportunity to be heard; it is taking necessary steps to reply suitably. The product is being manufactured and marketed by the company; it is also being supplied to a pharma company on principal to principal basis. The company has filed a petition in the Delhi High Court.

Published on July 12, 2018
This article is closed for comments.
Please Email the Editor